Prostate Cell News | Science News

A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules

January 20, 2026

[Cancer Research] To explore the utility of SWI/SNF therapy beyond androgen receptor (AR)-sensitive CRPC, scientists investigated SWI/SNF-targeting agents in AR-negative CRPC.

Reversing Enhancer RNA-Mediated IKBKE Gene Repression Enables Synthetic Anticancer Immunity in Prostate Cancer Models

January 20, 2026

[Journal of Clinical Investigation] Researchers demonstrate that androgen receptor pathway inhibitor plus irradiation triggered robust anticancer immunity in prostate cancers in both patients and mice.

Lactate Derived from Cancer-Associated Fibroblasts Promotes Alternative Splicing and Castration Resistance in Prostate Cancer

January 20, 2026

[Science Advances] The authors identified APCDD1+ cancer-associated fibroblasts as a distinct stromal population that secretes lactate into the tumor microenvironment in response to androgen deprivation therapy.

Regulation of Androgen Receptor Expression by Enhancer Elements in Prostate Cancer

January 20, 2026

[Experimental & Molecular Medicine] Elucidating the role of enhancer elements in driving androgen receptor (AR) overexpression and aberrant AR signaling may uncover new therapeutic targets for CRPC.

Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, a First-of-Its-Kind Treatment for Localized Prostate Cancer

January 9, 2026

[Alessa Therapeutics] Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.

Butterfly Medical Announces Completion of Pivotal Trial for Minimally Invasive Treatment of Benign Prostatic Hyperplasia

January 9, 2026

[Butterfly Medical (BioSpace)] Butterfly Medical, developer of a non-surgical solution for benign prostatic hyperplasia (BPH), announced the successful completion of the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study was designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy for BPH.

Sodium-Glucose Cotransporter 2 Inhibitors for Patients with Prostate Cancer Undergoing Hormone Therapy

January 9, 2026

[JAMA Oncology] In this cohort study with a target trial emulation design, sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering.

Uropathogenic Escherichia Coli Invade Luminal Prostate Cells via FimH-PPAP Receptor Binding

January 9, 2026

[Nature Microbiology] Researchers developed a 2D mouse stem cell-derived prostate epithelial organoid model. In the organoid model, 5α-dihydrotestosterone promoted differentiation of basal into luminal cells, while transcriptomic analyses validated the model in comparison to 3D models and mouse prostate tissue.

Unraveling the Microbial Landscape in Prostate Cancer: Pathogenesis to Therapy

January 8, 2026

[NPJ Biofilms and Microbiomes] The authors examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response.

Unraveling the Microbial Landscape in Prostate Cancer: Pathogenesis to Therapy

January 7, 2026

[NPJ Biofilms and Microbiomes] The authors examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response.

PEAK1 Promotes Prostate Cancer Progression and Docetaxel Resistance by Mediating the Polarization of Tumor-Associated Macrophages

January 7, 2026

[European Journal of Medical Research] Researchers investigated the role and mechanisms of pseudopodium-enriched atypical kinase (PEAK) 1 in prostate cancer progression and docetaxel resistance.

Circular RNA-Based Therapy Targeting Metabolic Vulnerability of Fatty Acid Synthesis Overcomes Castration-Resistant Prostate Cancer

January 7, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified circUTRN, an androgen receptor-inhibited circRNA that is upregulated following neoadjuvant hormonal therapy and downregulated in prostate cancer tissues.